Basit öğe kaydını göster

dc.contributor.authorCortoglu Koca, Sema
dc.date.accessioned2023-01-03T12:42:00Z
dc.date.available2023-01-03T12:42:00Z
dc.date.issued2022
dc.identifier.issn1303-2518en_US
dc.identifier.urihttp://hdl.handle.net/11727/8540
dc.description.abstractThe European Commission has signed advanced purchase agreements with various vaccine manufacturers for the production, purchase and supply of the COVID-19 vaccine in the EU. Some parts of the agreement texts with AstraZeneca, CurevacAg and Pfizer Inc./BioNTech have been blacked out. In these agreements, it is understood that Belgian courts are competent and Belgian law is chosen. In a dispute, it is possible for the competent courts to apply CISG since Belgium is a party to the CISG. Even if choice of law hasn't been made, the fact that the workplaces of all parties to these ageements are party to CISG, makes the CISG applicable. This study evaluates the applicability of the CISG to advanced purchase agreements (especially made with AstraZeneca) in EU Member States.en_US
dc.language.isoturen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectUnited Nations Convention on Contracts for the International Sale of Goods (CISG)en_US
dc.subjectAdvance Purchase Agreementen_US
dc.subjectCOVID-19 Vaccineen_US
dc.subjectApplicable Lawen_US
dc.subjectEuropean Unionen_US
dc.titleApplicability of the Vienna Sale Agreement (CISG) for Advanced Purchase Agreements of COVID-19 Vaccines in EU Member Statesen_US
dc.typearticleen_US
dc.relation.journalANKARA AVRUPA CALISMALARI DERGISI-ANKARA REVIEW OF EUROPEAN STUDIESen_US
dc.identifier.volume21en_US
dc.identifier.issue1en_US
dc.identifier.startpage133en_US
dc.identifier.endpage166en_US
dc.identifier.wos000830832500006en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster